Brett Strahin M.S.’s Post

Figure 3 The impact of lipoprotein(a) on atherosclerotic process and atherothrombosis. Lp(a) increases atherosclerotic plaque vulnerability, vascular smooth muscle cell proliferation and adhesion of molecules, chemotactic factors and plasma cytokines. Moreover, Lp(a) enhances platelet activation and aggregation and inhibits fibrinolysis by inhibiting plasminogen activation. Lp(a) inhibits TFPI and enhances expression of TF. Moreover, Lp(a) induces increased expression of PAI-1.

Formalin-fixed and paraffin embedded rat brain labeled with Rabbit Anti Integrin Alpha V + Beta 3 (CD51+CD61)Polyclonal Antibody, Unconjugated (bs-1310R) at 1:200 followed by conjugation to the secondary antibody and DAB staining. Receive a 20uL trial size for $89. Learn more at https://hubs.ly/Q02zjTd-0.

Polycythemia vera is a type of myeloproliferative neoplasm, a group of clonal malignancies characterized by excess hematopoiesis in myeloid cell lineages. Learn more: https://lnkd.in/eBEyEQvS

ACVRL1 is a transmembrane receptor protein consisting of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain with kinase activity. It is predominantly expressed in endothelial cells, which line the interior surface of blood vessels. ACVRL1 functions as a receptor for the ligands bone morphogenetic proteins (BMPs), specifically BMP9 and BMP10. Upon ligand binding, ACVRL1 forms a complex with type II receptors, such as BMPRII, leading to the activation of downstream signaling cascades. https://lnkd.in/eDq4bFjc #ACVRL1 #transmembranereceptor #ligandbinding #AlphaLifetech

ACVRL1 is a transmembrane receptor protein consisting of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular domain with kinase activity. It is predominantly expressed in endothelial cells, which line the interior surface of blood vessels. ACVRL1 functions as a receptor for the ligands bone morphogenetic proteins (BMPs), specifically BMP9 and BMP10. Upon ligand binding, ACVRL1 forms a complex with type II receptors, such as BMPRII, leading to the activation of downstream signaling cascades. https://lnkd.in/eSWXtC6S #ACVRL1 #transmembranereceptor #ligandbinding #AlphaLifetech

Formalin-fixed and paraffin embedded rat brain labeled with Rabbit Anti Integrin Alpha V + Beta 3 (CD51+CD61)Polyclonal Antibody, Unconjugated (bs-1310R) at 1:200 followed by conjugation to the secondary antibody and DAB staining. Receive a 20uL trial size for only $89. Learn more here: https://hubs.ly/Q02t99kP0.

Formalin-fixed and paraffin embedded rat brain labeled with Rabbit Anti Integrin Alpha V + Beta 3 (CD51+CD61)Polyclonal Antibody, Unconjugated (bs-1310R) at 1:200 followed by conjugation to the secondary antibody and DAB staining. Receive a 20uL trial size for only $89. Learn more here: https://hubs.ly/Q02zh-nr0.

Check out our new research article “Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity”. Abstract as follows: Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast cancer. Despite the development of several effective therapies targeting ERα signaling, clinical resistance remains a major challenge. In this study, we report the discovery of a new class of potent and orally bioavailable ERα degraders using the PROTAC technology, with ERD-3111 being the most promising compound. ERD-3111 exhibits potent in vitro degradation activity against ERα and demonstrates high oral bioavailability in mice, rats, and dogs. Oral administration of ERD-3111 effectively reduces the levels of wild-type and mutated ERα proteins in tumor tissues. ERD-3111 achieves tumor regression or complete tumor growth inhibition in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated models in mice. ERD-3111 is a promising ERα degrader for further extensive evaluations for the treatment of ER+ breast cancer.

Formalin-fixed and paraffin embedded rat brain labeled with Rabbit Anti Integrin Alpha V + Beta 3 (CD51+CD61)Polyclonal Antibody, Unconjugated (bs-1310R) at 1:200 followed by conjugation to the secondary antibody and DAB staining. Receive a 20uL trial size for only $89. Learn more here: https://hubs.ly/Q02G2sZJ0.

- Peripheral Blood Films from a Patient with beta-thalassemia Major, (A &B) - Note basophilic stippling, microcytosis, hypochromia, target cells, nucleated RBCs, and red cell fragments. (A, Wright- Giemsa stain; B, Wright-Giemsa stain.)